In prospective trials of osimertinib in LM in patients with EGFR-mutated NSCLC that had progressed with prior EGFR-directed TKI, the LM ORR was 41% with 160 mg daily [163] and 51.6% with 80 mg daily [164]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.